Related Experiment Video
Updated: Jul 11, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Revolutionizing cancer drug development: Harnessing the potential of basket trials
Vivek Subbiah1, Howard A Burris1, Razelle Kurzrock2,3
1Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Abstract:
The landscape of cancer therapy has been transformed by advances in clinical next-generation sequencing, genomically targeted therapies, and immunotherapies. Well designed clinical trials and efficient clinical trial conduct are crucial for advancing our understanding of cancer, improving patient outcomes, and identifying personalized treatments. Basket trials have emerged as one of the efficient modern clinical trial designs that evaluate the efficacy of these therapies across multiple cancer types based on specific molecular alterations or biomarkers, irrespective of histology or anatomic location. This review delves into the evolution of basket trials in cancer drug development, highlighting their potential prospects and current obstacles. The design of basket trials involves screening patients for specific molecular alterations or biomarkers and enrolling them in the trial to receive the targeted therapy under investigation. Statistical considerations play a crucial role in the design, analysis, and interpretation of basket trials. Several notable examples of basket trials that have led to US Food and Drug Administration approval for uncommon molecular alterations (e.g., NTRK fusions, BRAF mutations, RET and FGFR1 alterations) are discussed, including LOXO-TRK (ClinicalTrials.gov identifier NCT02122913)/SCOUT (ClinicalTrials.gov identifier NCT02637687)/NAVIGATE (ClinicalTrials.gov identifier NCT02576431)/STARTRK (ClinicalTrials.gov identifiers NT02097810, NT02568267), VE-BASKET (ClinicalTrials.gov identifier NCT01524978), ROAR Basket (ClinicalTrials.gov identifier NCT02034110), LIBRETTO-001 (ClinicalTrials.gov identifier NCT03157128), ARROW (ClinicalTrials.gov identifier NCT03037385), FIGHT-203 (ClinicalTrials.gov identifier NCT03011372), and the National Cancer Institute-Molecular Analysis for Therapy Choice trial (ClinicalTrials.gov identifier NCT02465060). Basket trials have the potential to revolutionize cancer treatment by identifying effective therapies for patients based on specific molecular alterations or biomarkers rather than traditional histology-based approaches. PLAIN LANGUAGE SUMMARY: To gain more knowledge about cancer, improve patient outcomes, and discover personalized treatments, it is crucial to conduct clinical trials efficiently. One effective type of clinical trial is called a basket trial. In basket trials, new treatments are tested on various types of cancer, regardless of their location in the body; instead, researchers focus on specific abnormalities in the cancer cells. Basket trials offer hope that we can find personalized treatments that are more effective for each individual battling cancer.
Insights
Basket trials efficiently test targeted cancer therapies across various cancer types based on molecular alterations, not histology. These innovative clinical trials are revolutionizing personalized cancer treatment and improving patient outcomes.
Area of Science:
- Oncology
- Clinical Trial Design
- Genomics
Background:
- Cancer therapy has advanced significantly with next-generation sequencing, targeted therapies, and immunotherapies.
- Efficient clinical trials are vital for advancing cancer research, improving patient outcomes, and developing personalized treatments.
- Basket trials represent a modern, efficient clinical trial design evaluating therapies across multiple cancer types based on molecular alterations.
Purpose of the Study:
- To review the evolution of basket trials in cancer drug development.
- To highlight the potential prospects and current obstacles associated with basket trials.
- To discuss notable examples of basket trials leading to FDA approval for specific molecular alterations.
Main Methods:
- Basket trial design involves screening patients for specific molecular alterations or biomarkers.
- Enrolled patients receive the targeted therapy under investigation.
- Statistical considerations are crucial for the design, analysis, and interpretation of basket trials.
Main Results:
- Several basket trials have led to US Food and Drug Administration (FDA) approval for uncommon molecular alterations.
- Examples include trials targeting NTRK fusions, BRAF mutations, and RET/FGFR1 alterations.
- Notable trials discussed include LOXO-TRK, VE-BASKET, ROAR Basket, LIBRETTO-001, ARROW, FIGHT-203, and the NCI-MoCha trial.
Conclusions:
- Basket trials have the potential to revolutionize cancer treatment by shifting focus from histology to molecular alterations.
- This approach enables the identification of effective therapies for patients based on specific biomarkers.
- Basket trials offer a promising avenue for developing personalized cancer treatments.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Clinical Trials: Overview